| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,301 |
3,851 |
$221K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,336 |
2,333 |
$147K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
2,559 |
2,340 |
$82K |
| 86328 |
|
1,827 |
966 |
$63K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,270 |
1,100 |
$52K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
250 |
248 |
$21K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,625 |
1,428 |
$20K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
459 |
459 |
$20K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
265 |
252 |
$18K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
439 |
406 |
$15K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
12 |
12 |
$5K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
339 |
177 |
$4K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
513 |
451 |
$4K |
| 99058 |
|
43 |
38 |
$3K |
| 99000 |
|
229 |
213 |
$1K |
| 81025 |
|
87 |
87 |
$591.79 |
| 81003 |
|
240 |
235 |
$409.67 |
| 99001 |
|
21 |
20 |
$115.92 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
27 |
27 |
$61.48 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
42 |
42 |
$43.11 |
| 99072 |
|
144 |
139 |
$0.00 |